These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 20960173)

  • 1. Hyperglycemia induced by tacrolimus and sirolimus is reversible in normal sprague-dawley rats.
    Shivaswamy V; McClure M; Passer J; Frahm C; Ochsner L; Erickson J; Bennett RG; Hamel FG; Larsen JL
    Endocrine; 2010 Jun; 37(3):489-96. PubMed ID: 20960173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tacrolimus and sirolimus induce reproductive abnormalities in female rats.
    Shivaswamy V; Ochsner L; Maroni D; Wang C; Passer J; Clure CE; Hamel FG; Davis JS; Larsen J
    Transplantation; 2011 Jun; 91(12):1333-9. PubMed ID: 21508897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tacrolimus and sirolimus have distinct effects on insulin signaling in male and female rats.
    Shivaswamy V; Bennett RG; Clure CC; Ottemann B; Davis JS; Larsen JL; Hamel FG
    Transl Res; 2014 Mar; 163(3):221-31. PubMed ID: 24361102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus and sirolimus cause insulin resistance in normal sprague dawley rats.
    Larsen JL; Bennett RG; Burkman T; Ramirez AL; Yamamoto S; Gulizia J; Radio S; Hamel FG
    Transplantation; 2006 Aug; 82(4):466-70. PubMed ID: 16926589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin improves immunosuppressant induced hyperglycemia and exocrine apoptosis in rats.
    Shivaswamy V; Bennett RG; Clure CC; Larsen JL; Hamel FG
    Transplantation; 2013 Jan; 95(2):280-4. PubMed ID: 23250335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute nephrotoxicity of tacrolimus and sirolimus in renal isografts: differential intragraft expression of transforming growth factor-beta1 and alpha-smooth muscle actin.
    Ninova D; Covarrubias M; Rea DJ; Park WD; Grande JP; Stegall MD
    Transplantation; 2004 Aug; 78(3):338-44. PubMed ID: 15316360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of metformin on hyperglycemia in an experimental model of tacrolimus- and sirolimus-induced diabetic rats.
    Jin J; Lim SW; Jin L; Yu JH; Kim HS; Chung BH; Yang CW
    Korean J Intern Med; 2017 Mar; 32(2):314-322. PubMed ID: 27688296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Conversion to CTLA4Ig on Tacrolimus-Induced Diabetic Rats.
    Jin L; Lim SW; Jin J; Luo K; Ko EJ; Chung BH; Lin HL; Yang CW
    Transplantation; 2018 Apr; 102(4):e137-e146. PubMed ID: 29319618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats.
    Lloberas N; Torras J; Alperovich G; Cruzado JM; Giménez-Bonafé P; Herrero-Fresneda I; Franquesa Ml; Rama I; Grinyó JM
    Nephrol Dial Transplant; 2008 Oct; 23(10):3111-9. PubMed ID: 18469305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of systemic immunosuppression on islet engraftment and function into a subcutaneous biocompatible device.
    Marzorati S; Bocca N; Molano RD; Hogan AR; Doni M; Cobianchi L; Inverardi L; Ricordi C; Pileggi A
    Transplant Proc; 2009; 41(1):352-3. PubMed ID: 19249555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of sirolimus alone with sirolimus plus tacrolimus in type 1 diabetic recipients of cultured islet cell grafts.
    Gillard P; Ling Z; Mathieu C; Crenier L; Lannoo M; Maes B; Roep B; Gorus F; Pipeleers D; Keymeulen B
    Transplantation; 2008 Jan; 85(2):256-63. PubMed ID: 18212631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined treatment of tacrolimus and everolimus increases oxidative stress by pharmacological interactions.
    Piao SG; Lim SW; Doh KC; Jin L; Heo SB; Zheng YF; Bae SK; Chung BH; Li C; Yang CW
    Transplantation; 2014 Jul; 98(1):22-8. PubMed ID: 24825522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tacrolimus- and sirolimus-induced human β cell dysfunction is reversible and preventable.
    Dai C; Walker JT; Shostak A; Padgett A; Spears E; Wisniewski S; Poffenberger G; Aramandla R; Dean ED; Prasad N; Levy SE; Greiner DL; Shultz LD; Bottino R; Powers AC
    JCI Insight; 2020 Jan; 5(1):. PubMed ID: 31941840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of tacrolimus and the development of posttransplant diabetes mellitus: a Brazilian single-center, observational study.
    Gnatta D; Keitel E; Heineck I; Cardoso BD; Rodrigues AP; Michel K; Garcia VD
    Transplant Proc; 2010 Mar; 42(2):475-8. PubMed ID: 20304169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
    Ho VT; Aldridge J; Kim HT; Cutler C; Koreth J; Armand P; Antin JH; Soiffer RJ; Alyea EP
    Biol Blood Marrow Transplant; 2009 Jul; 15(7):844-50. PubMed ID: 19539216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
    Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
    Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results.
    Guethoff S; Stroeh K; Grinninger C; Koenig MA; Kleinert EC; Rieger A; Mayr T; von Ziegler F; Reichart B; Hagl C; Schramm R; Kaczmarek I; Meiser BM
    J Heart Lung Transplant; 2015 May; 34(5):634-42. PubMed ID: 25701373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-administration of sirolimus alters tacrolimus pharmacokinetics in a dose-dependent manner in adult renal transplant recipients.
    Baldan N; Rigotti P; Furian L; Margani G; Ekser B; Frison L; De Martin S; Palatini P
    Pharmacol Res; 2006 Sep; 54(3):181-5. PubMed ID: 16750634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the mTOR pathway: A new mechanism of β cell toxicity induced by tacrolimus.
    Rodriguez-Rodriguez AE; Donate-Correa J; Rovira J; Cuesto G; Luis-Ravelo D; Fernandes MX; Acevedo-Arozena A; Diekmann F; Acebes A; Torres A; Porrini E
    Am J Transplant; 2019 Dec; 19(12):3240-3249. PubMed ID: 31152486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Empagliflozin on Tacrolimus-Induced Pancreas Islet Dysfunction and Renal Injury.
    Jin J; Jin L; Luo K; Lim SW; Chung BH; Yang CW
    Am J Transplant; 2017 Oct; 17(10):2601-2616. PubMed ID: 28422431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.